F Zölzer1, O Basu, P U Devi, S P Mohanty, C Streffer. 1. Department of Medical Radiobiology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. zoelzer@zsf.jcu.cz
Abstract
OBJECTIVES: Proliferating cell nuclear antigen (PCNA) has often been used as a marker to aid assessment of tumour growth fraction. This paper addresses the question of whether it can be used as an S-phase marker, when the non-chromatin-bound form of the protein is removed by pepsin treatment. MATERIALS AND METHODS: Cytofluorometric measurements were carried out after immunofluorescence staining of PCNA and counterstaining of DNA. S-phase fraction was determined with the help of windows on PCNA versus DNA scattergrams, or mathematically from DNA histograms. RESULTS: S-phase fractions obtained using the two methods correlated well, but did not always agree, exact discrepancies depending on the mathematical model used for histogram analysis. CONCLUSIONS: Determination of S-phase fractions with the help of PCNA immunofluorescence staining is possible, and probably more reliable than calculation of S-fractions from DNA histograms. It thus offers an alternative to assays involving BrdU labelling in vivo.
OBJECTIVES:Proliferating cell nuclear antigen (PCNA) has often been used as a marker to aid assessment of tumour growth fraction. This paper addresses the question of whether it can be used as an S-phase marker, when the non-chromatin-bound form of the protein is removed by pepsin treatment. MATERIALS AND METHODS: Cytofluorometric measurements were carried out after immunofluorescence staining of PCNA and counterstaining of DNA. S-phase fraction was determined with the help of windows on PCNA versus DNA scattergrams, or mathematically from DNA histograms. RESULTS: S-phase fractions obtained using the two methods correlated well, but did not always agree, exact discrepancies depending on the mathematical model used for histogram analysis. CONCLUSIONS: Determination of S-phase fractions with the help of PCNA immunofluorescence staining is possible, and probably more reliable than calculation of S-fractions from DNA histograms. It thus offers an alternative to assays involving BrdU labelling in vivo.
Authors: A Orfao; J Ciudad; M González; J F San Miguel; A R García; M C López-Berges; F Ramos; M C Del Cañizo; A Ríos; M Sanz Journal: Leukemia Date: 1992-01 Impact factor: 11.528
Authors: R García-Sanz; M I González-Fraile; G Mateo; J M Hernández; M C López-Berges; N de las Heras; J Fernández-Calvo; F Ortega; J A Portero; A Bárez; J Galende; A Orfão; J F San Miguel Journal: Int J Cancer Date: 2004-12-10 Impact factor: 7.396
Authors: Anil K Tripathi; Rupesh Chaturvedi; Rizwan Ahmad; Mohd Asim; Kamal K Sawlani; Manoj K Singh; Payal Tripathi; Babu L Tekwani Journal: Leuk Res Date: 2003-10 Impact factor: 3.156
Authors: G Tsirakis; C A Pappa; M Kaparou; V Katsomitrou; A Hatzivasili; T Alegakis; A Xekalou; E N Stathopoulos; M G Alexandrakis Journal: Eur J Histochem Date: 2011-08-27 Impact factor: 3.188
Authors: Wang Kai; Chen Lin; Yang Jin; He Ping-Lin; Liu Xun; Amend Bastian; Stenzl Arnulf; Xing Sha-Sha; Luo Xu; Cui Shu Journal: Mol Med Rep Date: 2020-04-24 Impact factor: 2.952